Thrivent Financial for Lutherans Sells 2,384 Shares of Innoviva, Inc. (NASDAQ:INVA)

Thrivent Financial for Lutherans decreased its position in Innoviva, Inc. (NASDAQ:INVA) by 5.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,234 shares of the biotechnology company’s stock after selling 2,384 shares during the quarter. Thrivent Financial for Lutherans owned 0.07% of Innoviva worth $835,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. American Century Companies Inc. lifted its stake in shares of Innoviva by 369.6% in the 2nd quarter. American Century Companies Inc. now owns 459,690 shares of the biotechnology company’s stock valued at $7,539,000 after acquiring an additional 361,797 shares during the last quarter. Marshall Wace LLP increased its stake in Innoviva by 823.3% in the 2nd quarter. Marshall Wace LLP now owns 204,752 shares of the biotechnology company’s stock worth $3,358,000 after purchasing an additional 182,575 shares during the period. Squarepoint Ops LLC bought a new stake in Innoviva in the second quarter valued at approximately $2,198,000. Denali Advisors LLC boosted its stake in shares of Innoviva by 34.9% during the second quarter. Denali Advisors LLC now owns 439,786 shares of the biotechnology company’s stock valued at $7,212,000 after purchasing an additional 113,700 shares during the period. Finally, Harbor Capital Advisors Inc. boosted its stake in shares of Innoviva by 394.0% during the second quarter. Harbor Capital Advisors Inc. now owns 94,895 shares of the biotechnology company’s stock valued at $1,556,000 after purchasing an additional 75,685 shares during the period. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Innoviva Stock Down 0.7 %

NASDAQ INVA opened at $18.99 on Wednesday. Innoviva, Inc. has a 1 year low of $13.94 and a 1 year high of $21.28. The stock has a market capitalization of $1.19 billion, a PE ratio of 27.52 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. The business’s 50-day moving average is $19.55 and its 200 day moving average is $18.28.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). The business had revenue of $89.51 million during the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. Sell-side analysts forecast that Innoviva, Inc. will post 0.33 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Innoviva from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 6th.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.